See the DrugPatentWatch profile for Zolinza
What is Zolinza used for?
Zolinza (vorinostat) is a cancer medicine. It is used for treatment of cutaneous T-cell lymphoma (CTCL) in adults when the disease has not responded to other treatments or has returned.[1]
How does Zolinza work?
Zolinza contains vorinostat, a type of drug called a histone deacetylase (HDAC) inhibitor. By inhibiting HDAC enzymes, it can affect gene expression in cancer cells, which helps slow or stop tumor growth in CTCL.[1]
What does Zolinza treat in cutaneous T-cell lymphoma?
For CTCL, Zolinza is indicated in adults with disease that has progressed despite at least one prior systemic therapy.[1]
What side effects are commonly associated with Zolinza?
Common side effects reported with vorinostat/Zolinza can include gastrointestinal symptoms (like nausea and diarrhea), fatigue, and changes in blood counts, along with other potential risks typical of cancer therapies.[1]
Is Zolinza still under patent, or are alternatives available?
Information on patents and exclusivity for vorinostat/Zolinza can be tracked via DrugPatentWatch, which compiles patent and market-authorization details and can help you see whether generic or other competitive options may be approaching.[2]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021035
[2] https://drugpatentwatch.com/